Coverage Policy Manual
Policy #: 2025028
Category: Pharmacy
Initiated: November 2025
Last Review: September 2026
Prademagene Zamikeracel (e.g., Zevaskyn)

Description:
Epidermolysis Bullosa (EB) is a rare inherited connective tissue disease. Dystrophic Epidermolysis Bullosa (DEB) is subtype EB caused from mutations in the COL7A1 gene producing dysfunctional type VII collagen protein. Normally the protein anchors the dermis layer of the skin to the epidermis. With the mutation, patients experience skin that blisters, nonhealing ulceration, scarring and fibrosis. Over time this leads to fusion of fingers and toes, loss of nails, contractures, and vision loss. DEB is subdivided into both recessive DEB (RDEB) and dominant DEB (DDEB) with recessive being the more severe form. Recurrent wounds heal but blister and reopen easily. Chronic wounds may take years to heal.
Prademagene Zamikeracel (e.g., Zevaskyn) is a topical gene therapy for RDEB using the patient’s own harvested skin cells modified to produce functional type VII protein. The produced sheets are applied to open chronic wounds through surgery to promote healing.
Regulatory Status
 
Prademagene Zamikeracel (e.g., Zevaskyn) was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
 
Coding
 
See CPT/HCPCS Code section below.

Policy/
Coverage:
Effective November 01, 2026
 
Does Not Meet Primary Coverage Criteria Or Is Not Covered For Contracts Without Primary Coverage Criteria
 
Prademagene Zamikeracel (e.g., Zevaskyn) does not meet member benefit certificate Primary Coverage Criteria that there be scientific evidence of effectiveness in improving health outcomes and is not covered for any indication or circumstance.
 
For contracts without Primary Coverage Criteria, Prademagene Zamikeracel (e.g., Zevaskyn) is considered not Medically Necessary and is not covered or is investigational for any indication or circumstance not described above. Not Medically Necessary or Investigational services are specific contract exclusions in most member benefit certificates of coverage.
 
Click the following link to view the specific criteria in InterQual®: https://prod.ds.interqual.com/service/connect/transparency?tid=27b0a724-ca06-4b22-846b-598b8dae52fc
 
Effective October 01, 2026 to October 31, 2026
 
Does Not Meet Primary Coverage Criteria Or Is Not Covered For Contracts Without Primary Coverage Criteria
 
Prademagene Zamikeracel (e.g., Zevaskyn) for the treatment of any indication or any circumstance is considered not Medically Necessary and is not covered or is investigational. Not Medically Necessary or Investigational services are Plan exclusions.
 
For members with contracts without Primary Coverage Criteria, Prademagene Zamikeracel (e.g., Zevaskyn) for any indication or circumstance not described above, is considered not Medically Necessary and is not covered or is Investigational. Not Medically Necessary or Investigational services are specific contract exclusions in most member benefit certificates of coverage.
 
Effective November 15, 2025 to September 30, 2026
 
Does Not Meet Primary Coverage Criteria Or Is Not Covered For Contracts Without Primary Coverage Criteria
 
Prademagene Zamikeracel (e.g., Zevaskyn), for all indications and circumstances, does not meet member benefit certificate primary coverage criteria that there be scientific evidence of effectiveness in improving health outcomes and is not covered.
 
For members with contracts without primary coverage criteria, Prademagene Zamikeracel (e.g., Zevaskyn), for all indications and circumstances, is considered investigational and is not covered. Investigational services are specific contract exclusions in most member benefit certificates of coverage.

Rationale:
The FDA approval of prademagene zamikeracel is based on the pivotal Phase 3 VIITAL™ study (NCT04227106), a multi-center, randomized, intrapatient-controlled trial that met its two co-primary efficacy endpoints demonstrating statistically significant healing of 50 percent or more from baseline in large chronic RDEB wounds, and pain reduction from baseline as assessed by the Wong-Baker FACES scale, as evaluated at six months after treatment.
 
Across 43 large and chronic wounds treated with a single application of prademagene zamikeracel, 81 percent of wounds showed 50 percent or more healing (P<0.0001) as evaluated at six months, compared to 16 percent in 43 matched control wounds treated with standard of care. The most common adverse events were observed in fewer than five percent of patients and included procedural pain and itch.
 
In the Phase 1/2a study of prademagene zamikeracel (NCT01263379), a single center, open label study in 38 chronic wounds across 7 patients showed that a single surgical application of prademagene zamikeracel was associated with long-term improvement at treated sites over a median follow-up of 6.9 years; range 4 to 8 years.
 
2026 Update
Annual policy review completed with a literature search using the MEDLINE database through September 2026. No changes to coverage statements.

CPT/HCPCS:
J3389Topical administration, prademagene zamikeracel, per treatment
J3590Unclassified biologics

References:
IPD Analytics RxInsights.(2021) Epidermolysis Bullosa: Disease Overview and Late-Stage Pipeline. Published March 2021. Accessed July 3, 2025. Subscription required.

IPD Analytics RxInsights.(2021) Epidermolysis Bullosa: Disease Overview and Late-Stage Pipeline. Published March 2021. Accessed July 3, 2025. Subscription required.

IPD Analytics RxInsights.(2021) Epidermolysis Bullosa: Disease Overview and Late-Stage Pipeline. Published March 2021. Accessed July 3, 2025. Subscription required.

IPD Analytics RxInsights.(2023) Trends in Recent Cell and Gene Therapy Approvals. Published August 2023. Accessed July 3, 2025. Subscription required.

IPD Analytics RxInsights.(2025) Zevaskyn (prademagene zamikeracel). Published June 2025. Accessed July 26, 2025. Subscription required.

Murrell DF.(2025) Overview of the management of epidermolysis bullosa. UpToDate, Connor RF (Ed), Wolters Kluwer. Accessed on July 11, 2025.

Okoro, Chinwe et.al.(2025) Clinical Review Memo-Zevaskyn FDA. Published April 2025. Accessed July 16, 2025.

Package Insert(2025) Zevaskyn Cleveland, OH: Abeona Therapeutics Inc.; 2025.

Rahman, Tanbin.(2025) Statistical Review-Zevaskyn. FDA. Published January 2025. Accessed July 16, 2025.

Tang JY, Marinkovich MP, Wiss K, et al.(2025) Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-center, randomized, open-label, intrapatient-controlled phase 3 trial.  Lancet. Published online June 23, 2025. doi:10.1016/S0140-6736(25)00778-0

Tang JY, Marinkovich MP, Wiss K, et al.(2025) Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. Lancet. Published online June 23, 2025. doi:10.1016/S0140-6736(25)00778-0


Group specific policy will supersede this policy when applicable. This policy does not apply to the Wal-Mart Associates Group Health Plan participants.
CPT Codes Copyright © 2026 American Medical Association.